Exelixis

Exelixis logo

Exelixis, Inc. is an American biotechnology company that focuses on the development of small molecule therapies for the treatment of cancer. The company is headquartered in Alameda, California.

History

Exelixis was founded in 1994 by Corey Goodman, George Scangos, and Stelios Papadopoulos. The company initially focused on model organism genetics to identify novel drug targets. Over time, Exelixis shifted its focus to the development of small molecule drugs for cancer treatment.

Products

Exelixis has developed several notable products, including:

• Cabozantinib - A small molecule inhibitor of multiple tyrosine kinases, used in the treatment of medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
• Cobimetinib - A MEK inhibitor used in combination with vemurafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma.

Research and Development

Exelixis continues to invest heavily in research and development, focusing on the discovery and development of new therapies for cancer. The company collaborates with various academic institutions and other biotechnology companies to advance its pipeline of investigational drugs.

Collaborations

Exelixis has established several strategic collaborations to enhance its research and development efforts. Notable collaborations include partnerships with Bristol-Myers Squibb, Roche, and Ipsen.

Corporate Governance

The company's leadership team includes experienced professionals from the biotechnology and pharmaceutical industries. The current CEO is Michael M. Morrissey, who has been with the company since 2000.

See also

• Biotechnology
• Cancer treatment
• Pharmaceutical industry
• Drug development

Related Pages

• Cabozantinib
• Cobimetinib
• Biotechnology
• Cancer treatment
• Pharmaceutical industry
• Drug development